|
Hepatitis B
|
0.400 |
Biomarker
|
disease |
CTD_human |
"Serum microRNA signatures as ""liquid biopsies"" for interrogating hepatotoxic mechanisms and liver pathogenesis in human."
|
28545106 |
2017 |
|
Hepatitis B
|
0.400 |
Biomarker
|
disease |
BEFREE |
<b>Results</b>: In total plasma samples, only miRNA-200b (HBV: <i>p</i> = 0.0384; HCV: <i>p</i> = 0.0069) and miRNA-122 (HBV: <i>p <</i> 0.0001; HCV: <i>p</i> = 0.0007) were significantly up-regulated during early fibrosis.
|
28232800 |
2017 |
|
Hepatitis B
|
0.400 |
Biomarker
|
disease |
BEFREE |
Hepatitis B virus-human chimeric transcript HBx-LINE1 promotes hepatic injury via sequestering cellular microRNA-122.
|
26409216 |
2016 |
|
Hepatitis B
|
0.400 |
Biomarker
|
disease |
BEFREE |
microRNA-122 abundance in hepatocellular carcinoma and non-tumor liver tissue from Japanese patients with persistent HCV versus HBV infection.
|
24130799 |
2013 |
|
Hepatitis B
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Aim of this study was to investigate the prognostic potential of plasma microRNA-122 levels in patients with hepatitis B virus (HBV)-related hepatocellular carcinoma after hepatic resection or radiofrequency ablation (RFA).
|
26129878 |
2015 |
|
Hepatitis B
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Association of miRNA-122-binding site polymorphism at the interleukin-1 α gene and its interaction with hepatitis B virus mutations with hepatocellular carcinoma risk.
|
24748463 |
2014 |
|
Hepatitis B
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Collectively, the findings of the present study may provide insight into the mechanistic role of HBV infection in modulating the expression of miR‑122, which targets the 3'UTR of APOBEC2 mRNA, subsequently inducing liver carcinogenesis.
|
31485598 |
2019 |
|
Hepatitis B
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Hepatic expression of miR-122 in HBV patients was not associated with viral load or liver injury.
|
27390784 |
2016 |
|
Hepatitis B
|
0.400 |
Biomarker
|
disease |
BEFREE |
However, the researches on the accuracy of miR122 detection in chronic viral hepatitis have been inconsistent, leading us to conduct this meta-analysis to systematically summarize the diagnostic value of circulating miR-122 in patients with hepatitis B virus (HBV) and/or hepatitis C virus (HCV)-associated chronic viral hepatitis.<b>Methods:</b> A comprehensive literature search (updated to January 30, 2019) in PubMed, Cochrane library, EMBASE, CNKI, Wanfang, and CQVIP databases was performed to identify eligible studies.
|
31427483 |
2019 |
|
Hepatitis B
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
In all, our study revealed that a number of miRNAs were differentially expressed during HBV infection and underscored the potential importance of miR-122 in the infection process.
|
21692939 |
2011 |
|
Hepatitis B
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
In contrast, miR-122 expression is reduced in nonalcoholic steatohepatitis (NASH) patients, and in a subset of hepatocellular carcinoma (HCC) patients including hepatitis B virus (HBV) positive patients with highly invasive and metastatic cancer.
|
25537773 |
2015 |
|
Hepatitis B
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
In cultured cells, HBV gene expression and replication reduces with increased expression of miR-122, and the expression of miR-122 decreases in the presence of HBV infection and replication.
|
21903935 |
2011 |
|
Hepatitis B
|
0.400 |
Biomarker
|
disease |
BEFREE |
In order to assess the sensitivity and reliability of these two class of RNAs as marker of hepatitis B or C induced chronic liver disease, we collected plasma samples from 156 chronic hepatitis B or C patients (HBV active n = 112, HBV carrier n = 19, hepatitis C n = 25) and 22 healthy donors and quantified their circulating mRNA for albumin, HP (haptoglobin), CYP2E1 (cytochrome P450, family 2, subfamily E) and ApoA2 (Apolipoprotein A2) in conjunction with microRNA-122, a well established marker for acute and chronic liver injury.
|
24643113 |
2014 |
|
Hepatitis B
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
In this study, miR-122 was down-regulated in the hepatitis B virus (HBV)-related HCC cell line HepG2.2.15 compared to HepG2.
|
21725618 |
2011 |
|
Hepatitis B
|
0.400 |
Biomarker
|
disease |
BEFREE |
In this study, we explored the clinical significance, transcriptional regulation, and direct target of miR-122 in hepatitis B virus (HBV)-associated hepatocellular carcinoma.
|
25422324 |
2015 |
|
Hepatitis B
|
0.400 |
Biomarker
|
disease |
BEFREE |
MiR-19a, miR-122 and miR-223 are differentially regulated by hepatitis B virus X protein and involve in cell proliferation in hepatoma cells.
|
27150195 |
2016 |
|
Hepatitis B
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Moreover, there was a significant correlation between serum miR-122 levels and the levels of HBV DNA, hepatitis B e-antigen, and HBV core-related antigen.
|
29896794 |
2018 |
|
Hepatitis B
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Moreover, we show that hepatitis B virus X protein binds PPARγ and inhibits the transcription of miR-122, whereas hepatitis C viral particles exhibited no significant effect; these findings provide mechanistic insight into reduction of miR-122 in patients with HBV but not with HCV infection.
|
23703729 |
2013 |
|
Hepatitis B
|
0.400 |
Biomarker
|
disease |
BEFREE |
Other biomarkers corresponded to common patterns of cellular injury, such as the liver-specific microRNA, miR-122, which was elevated in a disparate set of diseases that injure the liver primarily or secondarily including hepatitis B, hepatitis C, sepsis, and myocardial infarction.
|
24586876 |
2014 |
|
Hepatitis B
|
0.400 |
Biomarker
|
disease |
BEFREE |
Our results suggest that serum miR-122 might serve as a novel and potential noninvasive biomarker for detection of HCC in healthy subjects, moreover, it might serve as a novel biomarker for liver injury but not specifically for detection of HCC in chronic HBV infection patients.
|
22174818 |
2011 |
|
Hepatitis B
|
0.400 |
Biomarker
|
disease |
BEFREE |
Our study suggests that suppression of miR-122 induced by HBV infection, leads to the inactivation of IFN expression, which in turn enhances HBV replication, contributing to viral persistence and hepatocarcinogenesis.
|
25766860 |
2015 |
|
Hepatitis B
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Our study thereby reveals that under the unique condition of high abundance of miR-122 and viral mRNAs and much lower level of miR-122 target in HBV infection, HBV may have evolved to employ the miRNA-mediated virus and host mRNAs network for optimal fitness within hepatocytes.
|
26184825 |
2015 |
|
Hepatitis B
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Quantitative real-time polymerase chain reaction was utilized to determine serum miR-122 expression in 102 patients with different liver diseases [CHBLF (n = 58), acute hepatitis B (n = 10), chronic hepatitis B (n = 22) and hepatitis B-related cirrhosis (n = 12)] and 23 healthy controls.
|
27059663 |
2016 |
|
Hepatitis B
|
0.400 |
Biomarker
|
disease |
BEFREE |
Serum microRNA-122 and Wisteria floribunda agglutinin-positive Mac-2 binding protein are useful tools for liquid biopsy of the patients with hepatitis B virus and advanced liver fibrosis.
|
28475652 |
2017 |
|
Hepatitis B
|
0.400 |
Biomarker
|
disease |
BEFREE |
Serum also contains microRNAs, a class of small non-coding RNAs that play an important role in regulating gene expression. miR-122 is specific to the liver and correlates strongly with liver enzyme levels and necroinflammatory activity, and other microRNAs are correlated with the degree of fibrosis. miR-122 has also been found to be required for hepatitis C virus (HCV) infection, whereas other microRNAs have been shown to play antiviral roles. miR-125a-5p and miR-1231 have been shown to directly target hepatitis B virus (HBV) transcripts, and others are up- or down-regulated in infected individuals.
|
26927063 |
2016 |